FDA Draft Guidance: MRD Negativity & Complete Response as Accelerated Approval Endpoints in Multiple Myeloma

Here’s the extracted list of URLs from the provided HTML snippet:

1. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/minimal-residual-disease-and-complete-response-multiple-myeloma-use-endpoints-support-accelerated
2. https://www.fiercebiotech.com/biotech/fda-outlines-draft-policy-mrd-complete-response-accelerated-approvals-multiple-myeloma